Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

nses 2,398 2,663 9,465 5,864 ------- -------- Other income (expense) 29 297 120 88 ------- -------- Loss for the period before taxes and extraordinary gain 2,369 2,366 9,345 5,776 Income tax expense (recovery) 16 (2,515) 12 (2,100) ------- -------- Loss (income) for the period before extraordinary gain 2,385 (149) 9,357 3,676 Extraordinary gain - 4,428 - 4,428 ------- -------- Net loss (income) 2,385 (4,577) 9,357 (752) Redeemable convertible preferred share accretion - 417 - 1,973 ------- -------- Loss (income) attributable to common shareholders $ 2,385 $(4,160) $ 9,357 $ 1,221 Condensed Balance Sheets (unaudited) (in thousands) September 30, December 31, 2009 2008 Assets: Cash, cash equivalents and short term investments $12,473 $12,419 Amounts and investment tax credit receivable 31 1,243 Prepaid and other current assets 1,487 587 Property, equipment and other assets 593 541 ------- ------- Total assets $14,584 $14,790
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Applied DNA Sciences, Inc. (OTCQB: ... and product authentication solutions, will host a conference call ... third quarter results. The Quarterly Report on Form 10Q ... of the day on Monday August 11, 2014. ... conference call beginning at 9:00 A.M. Eastern Daylight Time ...
(Date:8/1/2014)... August 01, 2014 RURO, Inc., ... provider, today officially announces the opening of its ... Science Park, Baoshan District in Shanghai, PRC, RURO ... under the management of Mr. Shen Gang, the ... the past three years, RURO’s has installed FreezerPro-based ...
(Date:8/1/2014)... , Aug. 1, 2014 One of the ... of personalized medicine, which is the practice of using ... to a patient,s individual biology. Personalized diagnostics—laboratory analyses that ... role in the lab,s future. This fall, AACC ... the latest science in this exciting field and the ...
(Date:8/1/2014)... Research and Markets has announced the addition ... and Analysis Market 2014-2018" report to their offering. ... Single Nucleotide Polymorphism (SNP) genotyping is the screening and ... of various species. SNPs are commonly present in all ... analyze thousands of SNPs and has the potential for ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3RURO Opens Office in Shanghai, China 2First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2
... COLUMBIA, Md., Dec. 14 A&G Pharmaceutical announced,today ... Initiative,has awarded A&G an $870,000 grant to conduct ... proprietary breast cancer biomarker,GP88, in blood and tissue ... could provide the basis for developing a blood ...
... Embla Systems, a leader in the field of,sleep ... of an,exclusive agreement with the Beth Israel Deaconess ... Pulmonary Coupling (CPC) technology,developed by Drs. Robert Thomas, ... CPC technology represents a breakthrough in how sleep ...
... New Mexico, December 13, 2007In collaboration with the ... international team of researchers has, for the first ... mysterious metallic puddles that facilitate the transition of ... one. , The research may lead to a ...
Cached Biology Technology:A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 2A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 3Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology 2Collaboration yields 'the right glasses' for observing mystery behavior in electrons 2Collaboration yields 'the right glasses' for observing mystery behavior in electrons 3
(Date:8/1/2014)... Charan Ranganath of the UC Davis Center for ... National Security Science and Engineering Faculty Fellowship from ... million fellowship will support new work on learning ... UC Davis. , The new project aims to ... with activity in the cortex and hippocampus, brain ...
(Date:8/1/2014)... is tricky enough. Knowing what causes them at the ... of Iowa researchers have created the most detailed map ... long associated with blinding diseases, such as age-related macular ... in the choroid, which supplies blood and oxygen to ... differences in the abundance of proteins in different areas ...
(Date:8/1/2014)... 2014 The Journal of Nutrition Education and Behavior ... Educational Material (GEM) awards, which were presented at the ... "Nutrition Education Impact: Local to Global," in Milwaukee, Wisconsin, ... awards recognize the authors of the best article and ... by members of the JNEB Journal Committee and Board ...
Breaking Biology News(10 mins):A map for eye disease 2
... and Avalon Technology partner on new ... aviation-related ... Inc.,(OTC Bulletin Board: CTHH) ( http://www.catcherinc.com ), a leader ... Technology ( http://www.avalontechnology.com ), a leading,integrator of managed mobile ...
... resulting from higher CO2 could boost the amount ... new study looks at a poorly understood process ... Sayer, postdoctoral fellow at the Smithsonian Tropical Research ... University of Minnesotas Department of Ecology, Evolution and ...
... Boulder, CO, USA Two hundred years ago Lewis and ... deal of scientific research with its descriptions of territory acquired ... be disappointed by the absence of living megafauna, the area ... volume published by the Geological Society of America makes clear ...
Cached Biology News:CATCHER to be Deployed at Major U.S. Airline 2CATCHER to be Deployed at Major U.S. Airline 3CATCHER to be Deployed at Major U.S. Airline 4Complex carbon picture clearer 2
Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
... the HECT protein, E6-AP and ... suggests that this E2 is ... of non-""N-end rule"" protein substrates ... proteins as well as the ...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Biology Products: